Outcomes of a pilot study exploring the role of digital health coaching for men with prostate cancer.

Authors

Nathan Handley

Nathan Handley

Thomas Jefferson University, Philadelphia, PA

Nathan Handley, Kuang-Yi Wen, Sameh Gomaa, Ayako Shimada, Benjamin Leiby, Kelly Jean Brassil, Lindsey Jackson, Anne Calvaresi, Adam P. Dicker

Organizations

Thomas Jefferson University, Philadelphia, PA, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, Thomas Jefferson University, Department of Pharmacology and Experimental Therapeutics, Philadelphia, PA, The University of Texas MD Anderson Cancer Center, Houston, TX, Pack Health, Birmingham, AL, The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

Research Funding

Other Foundation
Philadelphia Prostate Cancer Biome Project

Background: As the most common cancer among men in the US, prostate cancer (PCa) affects nearly 250,000 men annually, accounting for over 13% of all new cancer cases. Health-related quality of life (HRQoL) during and post-treatment is impacted by sexual, urinary and bowel function which can persist for months or years after treatment completion. As individuals primarily manage such symptoms in the community setting there is a need for interventions that can address overall health and wellness concerns needs of men with PCa beyond the clinical setting. Digital health coaching (DHC) is one such solution that has potential to address HRQoL for individuals with cancer. Methods: The aim of this pilot study was to evaluate the feasibility of a DHC program for individuals with PCa. One hundred English-speaking men with PCa requiring active treatment within the past 2 years were recruited from across the Delaware Valley. Consented individuals were enrolled in a 3-month DHC program, consisting of a weekly call from a health advisor along with delivery of evidence-based supplemental content via text or email focused on exercise nutrition, physical, emotional and sexual health, as well as financial toxicity. Secondary endpoints evaluated the relationship between the DHC intervention and health self-efficacy, as measured by the Cancer Behavior Inventory-Brief Form (CBI-B), quality of life (EPIC-CP), financial toxicity (COST) and global health (PROMIS- SF10). Results: 82 individuals enrolled in the study for which the mean age was 68 years old (1.2 % Black, 2.4% Rural). The feasibility threshold of 60% was met with 58 individuals completing the 3-month program (proportion = 70.7%, 90% CI: 61.4, 78.9). Health self-efficacy improved with a mean change in CBI-B of 4.1 (95% CI: 0.4, 7.8). The financial toxicity improved with a mean score change of 2.5 (95% CI: 1.0, 4.0). All symptom scores of EPIC-CP were improved by showing a decrease of mean scores. PROMIS-GH also improved in both mental and physical health domains with mean changes of 0.5 and 1.4 (95% CIs for mental: -1.6, 2.6, for physical: -0.1, 2.8). Conclusions: DHC demonstrated feasibility in a cross-sectional population of men with PCA recruited in the community setting. Data suggest that HRQoL, health-self efficacy and global health can be positively impacted by DHC. Results support the further evaluation of DHC in larger RCTs.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cost, Value, and Policy; Health Equity and Disparities; Patient Experience

Track

Cost, Value, and Policy,Technology and Innovation in Quality of Care,Health Care Access, Equity, and Disparities,Patient Experience,Quality, Safety, and Implementation Science

Sub Track

Access to Treatment and Supportive Care

Citation

J Clin Oncol 39, 2021 (suppl 28; abstr 102)

DOI

10.1200/JCO.2020.39.28_suppl.102

Abstract #

102

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

First Author: Thilo Westhofen

Abstract

2024 ASCO Genitourinary Cancers Symposium

Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.

First Author: David Joseph Benjamin

First Author: Elissa C. Kranzler